CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.
Lipid modification - primary and secondary CVD prevention - Management
What lipid modification therapy should I offer for secondary prevention if a statin is not suitable?
- Consider offering a fibrate, modified-release nicotinic acid or a bile acid sequestrant.
- Evidence supporting the use of these drugs for secondary prevention is poor compared to statins.
- The decision to select a particular lipid-modifying drug should take into account patient preference and tolerability, comorbidities, multiple drug therapy, and the benefits and risks of treatment.
In depth
© NHS Institute for Innovation and Improvement